Epithalon 50mg

What is Epithalon?

Epithalon (also spelled Epitalon or Epithalone) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG). It was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, based on the amino acid composition of Epithalamin, a polypeptide extract derived from bovine pineal gland tissue. With a molecular weight of approximately 390 Da and the molecular formula C₁₄H₂₂N₄O₉, Epithalon is classified as a pineal gland bioregulatory peptide and belongs to the Khavinson family of short bioregulatory peptides.

Although Epithalon was originally synthesized as an analog of natural Epithalamin, it was not until 2017 that the AEDG sequence was directly identified in physiological pineal gland extract, confirming its natural endogenous origin (Khavinson et al., 2017). This discovery validated decades of research suggesting that Epithalon reproduces the geroprotective, neuroendocrine, and immunomodulatory effects of the full pineal extract. As a synthetic tetrapeptide, Epithalon is highly water-soluble, with a hydrophilicity index of −8.5, and demonstrates remarkable bioactivity even at ultra-low concentrations. Research over the past 25+ years has documented Epithalon's capacity to activate telomerase, stimulate melatonin production, modulate gene expression, and extend lifespan in multiple animal models—making it one of the most extensively studied anti-aging peptides in the bioregulator class.

Mechanism of Action

Epithalon exerts its biological effects through multiple interconnected molecular pathways, a complexity that reflects its tissue-specific activity on subcortical structures—particularly the pineal gland. Research suggests that Epithalon's mechanisms operate at both the genetic and epigenetic level, making it unique among short peptides studied for aging research.

Telomerase Activation and Telomere Elongation

The most well-documented mechanism of Epithalon involves the activation of telomerase, the ribonucleoprotein enzyme responsible for maintaining telomere length at chromosome ends. In a landmark study, Khavinson et al. (2003) demonstrated that addition of Epithalon to telomerase-negative human fetal fibroblast cultures induced expression of the catalytic subunit (hTERT), activated telomerase enzymatic activity, and promoted telomere elongation—averaging a 33.3% increase in telomere length. This finding was confirmed using the telomere repeat amplification protocol (TRAP), where treated fibroblasts showed high telomere lengths during the G1 phase of the cell cycle. A subsequent study showed that Epithalon-treated human fetal fibroblasts continued dividing past the 44th passage, while untreated control cultures ceased mitosis after the 34th passage (Khavinson et al., 2004).

Epigenetic Regulation via DNA and Histone Binding

Molecular modeling and fluorescence studies have revealed that Epithalon can penetrate cell membranes, enter the nucleus, and interact directly with specific DNA sequences—particularly CAG regions that serve as methylation targets. Additionally, molecular docking analyses demonstrate that Epithalon binds preferentially to linker histones H1/6 (binding energy: −64.51 kcal/mol) and H1/3 (−56.49 kcal/mol) at sites that interact with DNA. This histone-binding activity suggests an epigenetic mechanism whereby Epithalon competes with histones for DNA binding, potentially increasing the probability of transcription at specific gene loci (Khavinson et al., 2020).

Pineal Gland Regulation and Melatonin Synthesis

Epithalon demonstrates tissue-specific tropism for the pineal gland. In pinealocyte cultures, it significantly increases arylalkylamine-N-acetyltransferase (AANAT) activity and pCREB transcription factor expression—both critical enzymes in the melatonin biosynthesis pathway (Khavinson et al., 2012). In aged rhesus monkeys, intramuscular administration of Epithalon produced a three-fold increase in nocturnal melatonin levels while normalizing cortisol circadian rhythms (Goncharova et al., 2001). Epithalon also modulates circadian gene expression, including upregulation of the Cry2 gene and downregulation of Clock and Csnk1e genes in human leukocytes.

Research Applications

Epithalon has been investigated across a remarkably broad spectrum of research areas. Its multi-pathway mechanism of action has made it a subject of interest in aging biology, oncology, neuroendocrinology, and regenerative science. Below are the primary research applications documented in published literature.

Anti-Aging and Longevity Research

Epithalon is one of the few peptides demonstrated to extend lifespan across multiple species. In CBA mice, long-term subcutaneous administration resulted in a 4-fold increase in the number of animals reaching 23 months of age compared to controls, with the oldest treated mice surviving to 34 months versus 24 months in the control group (Anisimov & Khavinson, 2010). In Drosophila melanogaster, Epithalon increased lifespan of imago flies by up to 16% when administered at the larval stage—notably at doses 16,000-fold lower than melatonin required to achieve comparable effects. These findings, combined with its telomerase-activating properties, position Epithalon as a leading compound in anti-aging peptide research. Related peptides such as GHK-Cu are frequently studied alongside Epithalon in the context of cellular senescence.

Circadian Rhythm and Melatonin Regulation

A clinical study on 75 women demonstrated that sublingual Epithalon (0.5 mg/day for 20 days) increased urinary 6-sulfatoxymelatonin excretion by 1.6 times compared to placebo, indicating enhanced pineal melatonin synthesis. The study also documented significant changes in circadian gene expression: Cry2 expression doubled while Clock and Csnk1e expression decreased (Araj et al., 2025). In aged rhesus monkeys, Epithalon stimulated evening melatonin synthesis and normalized the cortisol circadian rhythm, effects observed exclusively in older animals (Goncharova et al., 2005). These findings are relevant to researchers studying Pinealon and other pineal bioregulators. For more on sleep-related peptide research, see our guide on peptides for brain health.

Cancer and Tumor Biology Research

Epithalon has shown anti-tumor properties in multiple animal models. In CBA mice, long-term administration reduced overall tumor incidence significantly (p < 0.05). In FVB/N female mice transfected with the HER-2/neu breast cancer gene, Epithalon decreased the total number of mammary adenocarcinomas (p < 0.05) and reduced HER-2/neu mRNA expression 3.7-fold compared to controls. Additionally, in a 1,2-dimethylhydrazine-induced colon carcinogenesis model in rats, Epithalon significantly decreased cancer incidence and was found to be most effective when administered throughout all stages of cancer development. Molecular docking studies have also shown that Epithalon possesses binding strength to amino acid transporters LAT1, LAT2, and PEPT1 comparable to known inhibitors, suggesting a potential mechanism for its anti-proliferative effects.

Neuroprotection and Neurogenesis

Epithalon demonstrates notable neuroprotective and neurogenic properties. In human gingival mesenchymal stem cells, Epithalon increased mRNA expression of neuronal differentiation markers—Nestin, GAP43, β-tubulin III, and Doublecortin—by 1.6 to 1.8 times (Khavinson et al., 2020). In neuroblastoma NB7 cells cultured under hypoxic conditions, Epithalon fully prevented the decrease in neprilysin (NEP) and insulin-degrading enzyme (IDE) mRNA synthesis. Epithalon also affected acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activity in SH-SY5Y neuroblastoma cells, suggesting potential relevance to cholinergic deficiency research. Researchers studying neuroprotective peptides may also be interested in Semax and Selank, which target complementary neurological pathways. See our comparison at Selank vs Semax.

Retinal Degeneration Research

Epithalon has been studied extensively in retinitis pigmentosa models. In Campbell rats, parabulbar injections of Epithalon preserved all retinal layers at day 41, while untreated animals showed complete retinal destruction. Electroretinogram measurements indicated that Epithalon prolonged the functional activity of the retina by 43.9%, with even better results (two-fold extension) when administered during pregnancy and throughout life. A clinical trial at the St. Petersburg Institute of Bioregulation and Gerontology involving 162 retinitis pigmentosa patients showed that Epithalon (5.0 µg per eye, parabulbar injection for 10 days) significantly increased visual acuity and expanded peripheral visual fields, with 64.8% of patients experiencing a total visual field border expansion of 90–120 degrees.

Published Research Studies

Epithalon has been the subject of extensive peer-reviewed research spanning more than two decades. Below are key published studies that have shaped our understanding of this bioregulatory peptide.

1. Telomerase Activation in Human Somatic Cells (2003)
Khavinson VK, Bondarev IE, Butyugov AA published in the Bulletin of Experimental Biology and Medicine demonstrating that Epithalon induced telomerase catalytic subunit expression, enzymatic activity, and telomere elongation (averaging 33.3%) in human fetal fibroblasts—the first study to directly link Epithalon to telomerase reactivation in somatic cells.

2. Overcoming the Hayflick Limit (2004)
Khavinson VK, Bondarev IE, Butyugov AA, Smirnova TD demonstrated in the Bulletin of Experimental Biology and Medicine that Epithalon-treated human fetal fibroblasts continued dividing past the 44th passage, while control cultures lost mitotic ability at the 34th passage—providing direct evidence that Epithalon can extend the replicative lifespan of human cells beyond the Hayflick limit.

3. Neuroendocrine Restoration in Aged Primates (2001)
Goncharova ND, Khavinson VK, et al. reported in Neuroendocrinology Letters that Epithalon significantly stimulated evening melatonin synthesis in senescent rhesus monkeys (ages 20–26 years), producing a three-fold increase in nocturnal melatonin peaks while normalizing the circadian rhythm of cortisol secretion.

4. AEDG Peptide in Neurogenesis (2020)
Khavinson V, Diomede F, Mironova E, et al. published in Molecules showing that Epithalon increased neurogenic differentiation markers (Nestin, GAP43, β-tubulin III, Doublecortin) by 1.6–1.8 fold in human gingival mesenchymal stem cells, with molecular modeling demonstrating preferential binding to linker histones H1/6 and H1/3 at DNA-interacting sites.

5. Comprehensive Bioactivity Review (2025)
Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł published the most comprehensive review of Epithalon to date in the International Journal of Molecular Sciences, consolidating 25 years of in vitro, in vivo, and in silico research—covering telomerase activation, antioxidant properties, antitumor effects, neuroprotection, and circadian rhythm regulation.

Dosage Protocols in Research

The following dosage information is derived from published animal and in vitro studies and is provided for research purposes only. Epithalon is not approved for human therapeutic use.

In Vivo Research Dosages

In rodent longevity studies, Epithalon was typically administered via subcutaneous injection at doses of 0.1–1.0 µg per mouse, five times per week, in protocols lasting from several months to the natural lifespan of the animals. In rat studies, dosing ranged from 0.5 µg/rat for pineal gland studies to 5 µg/kg for immunological and radiation protection research, given intraperitoneally or subcutaneously for periods of 5–42 days. In non-human primate studies involving aged rhesus monkeys, intramuscular injections of Epithalon were used with monitoring periods of 10 days or more.

In Vitro Research Concentrations

Cell culture studies have utilized Epithalon at concentrations ranging from 10⁻¹⁷ M (ultra-low dose studies on murine thymocytes) to 2 mM (oocyte protection studies). The most commonly effective in vitro concentrations range from 0.01 µg/mL (neurogenesis studies) to 0.1 mM (oocyte research). Notably, Epithalon has demonstrated a non-linear dose-response pattern in some models, with optimal effects observed at moderate rather than maximal concentrations.

Reconstitution for Research

Epithalon lyophilized powder should be reconstituted with bacteriostatic water or sterile saline. Due to its high hydrophilicity, Epithalon dissolves readily in aqueous solutions. Researchers should refer to our comprehensive guide on how to reconstitute peptides for detailed protocols.

Storage and Handling

Proper storage is essential for maintaining the integrity and bioactivity of Epithalon peptide. As a lyophilized tetrapeptide, Epithalon is relatively stable compared to larger peptide sequences, but standard peptide storage protocols should still be followed.

Lyophilized (unreconstituted) powder: Store at −20°C for long-term storage (up to 24 months) or 2–8°C for short-term storage (up to 3 months). Keep in the original sealed container, protected from light and moisture. The lyophilized form is the most stable state for Epithalon.

Reconstituted solution: Once reconstituted with bacteriostatic water, store at 2–8°C and use within 4 weeks for optimal stability. Aliquoting into single-use volumes is recommended to minimize freeze-thaw cycles. If long-term storage of reconstituted Epithalon is required, flash-freezing aliquots and storing at −20°C is advisable, though each freeze-thaw cycle may reduce potency.

General handling: Minimize exposure to heat, direct sunlight, and repeated temperature fluctuations. Always use sterile technique when handling reconstituted peptide solutions. Epithalon has been noted in the literature as a low-hydrolysable peptide, which contributes to its relative stability. For comprehensive storage guidance, see our article on how to store research peptides.

Safety Profile in Research

Epithalon has demonstrated a favorable safety profile across extensive preclinical research. Across published studies spanning more than 25 years, the peptide has consistently shown low toxicity and good tolerability in multiple species.

Animal studies: In long-term rodent studies lasting up to the natural lifespan of mice, Epithalon administration at standard research doses (0.1–1.0 µg/mouse) did not significantly affect body weight, food consumption, or muscular strength. Epithalon was confirmed to be non-nephrotoxic in rats, and in some models actually demonstrated nephroprotective properties, including improved renal function in cisplatin-induced acute kidney failure (Araj et al., 2025). No genotoxic effects were observed; in fact, Epithalon demonstrated antimutagenic properties when co-administered with known mutagens such as zinc, cobalt, and nickel.

Clinical observations: In a clinical trial involving 162 retinitis pigmentosa patients receiving parabulbar Epithalon injections (5.0 µg per eye for 10 consecutive days), none of the treated patients reported adverse side effects. A separate study involving 75 women receiving sublingual Epithalon (0.5 mg/day for 20 days) also documented no significant adverse events.

Antioxidant and cytoprotective effects: Epithalon has consistently demonstrated antioxidant properties, including reduced lipid peroxidation in brain and liver tissues, decreased reactive oxygen species (ROS) in cell cultures and Drosophila models, and increased SOD-1, NQO1, and catalase gene expression in human fibroblasts. These properties suggest a protective rather than harmful profile. For a broader discussion of peptide safety, visit our research peptide safety guide.

Related Peptides

Epithalon belongs to the Khavinson bioregulator peptide family, a class of short peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology, each targeting specific organ systems. Related bioregulators include Thymalin (thymus bioregulator), Vilon (immune bioregulator), Cartalax (cartilage bioregulator), and Pinealon (brain bioregulator). Among these, Pinealon (EDR) shares Epithalon's affinity for pineal and neural tissue.

Beyond the Khavinson bioregulators, Epithalon's anti-aging properties invite comparison with GHK-Cu, a copper peptide complex also studied for gene expression modulation and tissue regeneration (see our GHK-Cu guide). Thymosin Alpha-1 shares Epithalon's immunomodulatory research applications, while NAD+ targets complementary cellular aging pathways through sirtuin activation and mitochondrial support (see our NAD+ research guide). For a comprehensive overview, consult our Epithalon anti-aging research guide and our broader article on peptides for anti-aging research.

Frequently Asked Questions

What is Epithalon used for in research?

Epithalon is primarily studied in anti-aging and longevity research due to its demonstrated ability to activate telomerase and elongate telomeres in human somatic cells. Research applications also include circadian rhythm regulation, melatonin production, cancer biology, neuroprotection, neurogenesis, retinal degeneration, and immunomodulation. It is one of the most comprehensively studied peptide bioregulators in gerontology research.

How does Epithalon activate telomerase?

Research indicates that Epithalon activates telomerase through multiple mechanisms. It directly induces expression of the hTERT catalytic subunit of telomerase and interacts with specific DNA sequences (particularly ATTTC) found in the telomerase gene promoter region. Additionally, Epithalon binds to linker histones H1/3 and H1/6 at DNA-interacting sites, potentially modifying chromatin structure to increase transcriptional access to telomerase-related genes.

What is the difference between Epithalon and Epithalamin?

Epithalamin is a complex polypeptide extract derived from bovine pineal gland tissue, while Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) designed to replicate the key active component of Epithalamin. Research indicates that Epithalon reproduces most of Epithalamin's geroprotective effects, and in some studies—particularly antioxidant assays in Drosophila—Epithalon demonstrated superior activity at doses 1,000-fold lower than Epithalamin.

What species have been used in Epithalon research?

Epithalon has been studied across a wide range of biological models including human cell cultures (fibroblasts, lymphocytes, stem cells, neuroblastoma lines), Drosophila melanogaster, multiple mouse strains (CBA, SHR, HER-2/neu transgenic, SAMP-1, C3H/He), various rat strains (Wistar, LIO, Campbell), rhesus monkeys (Macaca mulatta), rabbits, and even plant models (Nicotiana tabacum). Human clinical trials have also been conducted.

Can Epithalon cross cell membranes?

Yes. Studies using fluorescein isothiocyanate-labeled Epithalon on HeLa cell cultures demonstrated that the tetrapeptide can permeate the cell membrane and subsequently enter the nucleus. This ability to reach intracellular and nuclear compartments is thought to underlie its capacity to interact directly with DNA and histone proteins, thereby modulating gene expression.

What is the molecular weight of Epithalon?

Epithalon (Ala-Glu-Asp-Gly) has a molecular weight of approximately 390 Da in its free acid form. It is commercially available as the free base or as salts with acetic acid or trifluoroacetic acid (TFA) counterions. The small molecular weight contributes to its favorable solubility and cellular permeability.

How does Epithalon compare to other anti-aging peptides?

Epithalon is unique in its direct telomerase-activating mechanism, a property not shared by most other peptides studied in aging research. While GHK-Cu modulates gene expression related to tissue remodeling and antioxidant defense, and NAD+ targets mitochondrial and sirtuin pathways, Epithalon addresses the fundamental telomere-shortening mechanism of cellular aging. Its pineal gland-specific tropism and melatonin-boosting effects add a neuroendocrine dimension not found in most other anti-aging peptides.

Why Buy Epithalon from Iron Peak Peptides?

At Iron Peak Peptides, every batch of Epithalon 50mg undergoes rigorous third-party testing to guarantee ≥99% purity, verified through High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). Each order ships with a quality assurance documentation so you can verify the identity, purity, and potency of your research material before use.

Our Epithalon is manufactured in ISO-certified facilities under strict Good Manufacturing Practice (GMP) standards, ensuring consistent quality and batch-to-batch reproducibility. The 50mg vial size is optimized for extended research protocols, providing excellent value for laboratories conducting long-term telomerase, circadian rhythm, or longevity studies. We offer fast, discreet shipping with proper cold-chain handling to preserve peptide integrity from our facility to your lab. Our knowledgeable customer support team is available to answer technical questions about reconstitution, storage, and research applications. When it comes to research-grade Epithalon, Iron Peak Peptides delivers the purity, consistency, and reliability that your science demands.

References

1. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells. Bull Exp Biol Med. 2003;135(6):590-592.
2. Khavinson VK, Bondarev IE, Butyugov AA, Smirnova TD. Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell. Bull Exp Biol Med. 2004;137(6):613-616.
3. Khavinson VK. Peptides and Ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144.
4. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: Results and prospects. Biogerontology. 2010;11(2):139-149.
5. Goncharova ND, Khavinson VK, Lapin BA. Synthetic tetrapeptide Epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuroendocrinol Lett. 2001;22(4):251-254.
6. Goncharova ND, Khavinson VK, Lapin BA. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Exp Gerontol. 2005;40(1-2):51-57.
7. Khavinson V, Diomede F, Mironova E, et al. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020;25(3):609.
8. Khavinson VK, Linkova NS, Kvetnoy IM, et al. Molecular Cellular Mechanisms of Peptide Regulation of Melatonin Synthesis in Pinealocyte Culture. Bull Exp Biol Med. 2012;153(2):255-258.
9. Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691.
10. Khavinson VK, et al. Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Blood Lymphocytes. Bull Exp Biol Med. 2019;168(1):141-144.
11. Khavinson VK, Linkova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016;162(2):288-292.
12. Khavinson VK, et al. Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland. Bull Exp Biol Med. 2017;164(1):41-43.
13. Khavinson VK, Anisimov VN. Aging of the Pineal Gland. Usp Fiziol Nauk. 2002;33(4):42-50.